Pictet Asset Management Ltd. trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 0.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 306,769 shares of the medical device company’s stock after selling 1,851 shares during the period. Pictet Asset Management Ltd. owned 0.35% of DexCom worth $15,009,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of DXCM. UBS Group AG raised its stake in shares of DexCom by 11.1% during the first quarter. UBS Group AG now owns 20,317 shares of the medical device company’s stock worth $1,721,000 after buying an additional 2,038 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of DexCom by 12.3% during the first quarter. AQR Capital Management LLC now owns 74,211 shares of the medical device company’s stock worth $6,288,000 after buying an additional 8,137 shares during the last quarter. Skandinaviska Enskilda Banken AB publ raised its stake in shares of DexCom by 175.7% during the first quarter. Skandinaviska Enskilda Banken AB publ now owns 11,029 shares of the medical device company’s stock worth $934,000 after buying an additional 7,029 shares during the last quarter. Independent Portfolio Consultants Inc. raised its stake in shares of DexCom by 0.4% during the second quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock worth $183,000 after buying an additional 9 shares during the last quarter. Finally, Handelsbanken Fonder AB raised its stake in shares of DexCom by 115.0% during the second quarter. Handelsbanken Fonder AB now owns 21,500 shares of the medical device company’s stock worth $1,573,000 after buying an additional 11,500 shares during the last quarter.

DexCom, Inc. (NASDAQ DXCM) opened at $49.94 on Tuesday. The company has a current ratio of 5.86, a quick ratio of 5.50 and a debt-to-equity ratio of 0.84.

In other DexCom news, EVP Richard Doubleday sold 1,635 shares of the stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $75.26, for a total value of $123,050.10. Following the completion of the sale, the executive vice president now owns 72,395 shares in the company, valued at $5,448,447.70. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Andrew K. Balo sold 3,244 shares of the stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $71.18, for a total transaction of $230,907.92. The disclosure for this sale can be found here. In the last quarter, insiders sold 23,208 shares of company stock valued at $1,597,567. Corporate insiders own 1.70% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Pictet Asset Management Ltd. Trims Stake in DexCom, Inc. (DXCM)” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.watchlistnews.com/pictet-asset-management-ltd-trims-stake-in-dexcom-inc-dxcm/1685143.html.

DXCM has been the subject of a number of recent research reports. TheStreet downgraded shares of DexCom from a “c-” rating to a “d+” rating in a research note on Wednesday, October 25th. ValuEngine raised shares of DexCom from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Wedbush reissued a “buy” rating and set a $76.00 price target on shares of DexCom in a research note on Wednesday, October 4th. Robert W. Baird reissued a “hold” rating and set a $79.00 price target on shares of DexCom in a research note on Sunday, September 10th. Finally, Barclays PLC assumed coverage on shares of DexCom in a research note on Friday, September 15th. They issued an “equal weight” rating and a $76.00 target price for the company. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $70.69.

DexCom Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.